EUCTR2013-002651-15-NL进行中（未招募）1 期
Adjusting infliximab dose in IBD patients in remission, based on infliximab trough levels: the study on Infliximab Levels in IBD patients Steering Treatment, the ILIST pilot - ILIST-study
Zon MW0 个研究点开始时间: 2013年9月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Written informed consent
- •Patients with inflammatory bowel disease (IBD) treated with infliximab (IFX)
- •In clinical remission for 12 months after initiation of infliximab, supported by endoscopy when available
- •Fecal calprotectin < 250 µg/g
- •Permitted concomitant therapy: aminosalicylates, thiopurines and methotrexate at stable dose for at least 12 weeks
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Concomitant corticosteroid usage
- •Pregnancy or lactation
- •Other significant medical illness that might interfere with this study (such as current malignancy, immunodeficiency syndromes and psychiatric illness)
研究者
相似试验
尚未招募
不适用
Adjusting infliximab dose in patients with inflammatory bowel disease, based on blood levels.Inflammatory Bowel Disease, in remission with infliximab treatment.NL-OMON27672Erasmus MC Rotterdam40
招募中
不适用
owering infliximab dose in IBD patients in remission, based on infliximab trough levels: the study on Lowering Infliximab in IBD patients in sustained Remission, the LIR study10017969Inflammatory Bowel DiseaseNL-OMON44819Erasmus MC, Universitair Medisch Centrum Rotterdam110
进行中（未招募）
不适用
Infliximab dosing based on blood concentrations in patients with sarcoidosis: smart dosingSarcoidosisEUCTR2014-002224-26-NLSt. Antonius Hospital
撤回
4 期
A new dosing strategy of infliximab versus standard dosing in patients with severe sarcoidosis: optimization of treatment1002766510024967SarcoidosisNL-OMON42033Sint Antonius Ziekenhuis70
进行中（未招募）
不适用
A Study of Dose Optimization of Infliximab in the Treatment of Moderate to Severe Plaque Psoriasis. - DOSEModerate to severe plaque PsoriasisMedDRA version: 11.0Level: LLTClassification code 10037153Term: <Manually entered code. Term in E.1.1>EUCTR2008-000454-12-GRSchering Plough Research Institute, a Division of Schering Corporation200